Company News
Abbott to supply over 1 million COVID-19 antibody tests to India
Abbott will supply over one million of its laboratory-based serology blood test for the detection of the antibody, IgG (immunoglobulin G), that identifies if a person has had the novel coronavirus (COVID-19). The company is already in the process of delivering antibody tests to leading government and private hospitals, and labs in Maharashtra, Delhi, West Bengal, Uttar Pradesh, Jammu and Kashmir, and Gujarat. Abbott’s SARS-CoV-2 IgG test specifically identifies the IgG antibody, which is a protein that the body produces in the late stages of infection, and may remain for up to months and possibly years after a person has recovered.
Narendra Varde
GM and Country Head, Diagnostics Business in India,
Abbott
“Abbott is pleased to contribute to Indian Council of Medical Research’s COVID-19 antibody testing strategy to use IgG CLIA antibody tests. Abbott’s recently launched SARS-CoV-2 IgG test can be used to understand the spread of transmission in high-risk populations, such as healthcare workers, immune-compromised individuals, frontline workers, or those in containment zones. These tests also provide valuable information to the public health officials about the spread in asymptomatic cases, helping us assess the impact of our public health efforts now, and guide our COVID-19 response moving forward.”
